An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10) in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma.

Trial Profile

An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10) in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Lorvotuzumab mertansine (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ImmunoGen
  • Most Recent Events

    • 20 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2014 Planned End Date changed from 1 Jul 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 22 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top